Direct-to-consumer/NN
genetic/JJ
testing/NN
:/:
advantages/NNS
and/CC
pitfalls/NNS
./.
====================
Conventional/JJ
genetic/JJ
testing/NN
is/VBZ
a/DT
process/NN
in/IN
which/WDT
clinicians/NNS
take/VBP
samples/NNS
from/IN
patients/NNS
as/IN
clinically/RB
needed/VBN
,/,
send/VBP
them/PRP
to/TO
a/DT
laboratory/JJ
for/IN
genetic/JJ
testing/NN
,/,
and/CC
discuss/VBP
the/DT
test/NN
results/VBZ
with/IN
patients/NNS
./.
====================
Direct-to-consumer/JJ
(/(
DTC/NN
)/)
genetic/JJ
testing/NN
is/VBZ
different/JJ
from/IN
conventional/JJ
genetic/JJ
testing/NN
in/IN
that/DT
consumers/VBZ
learn/NN
about/RB
DTC/NN
genetic/JJ
testing/NN
from/IN
TV/NN
commercials/NNS
,/,
the/DT
internet/JJ
,/,
or/CC
in-store/RB
advertising/VBG
,/,
and/CC
request/VBP
the/DT
tests/NNS
to/TO
be/VB
performed/VBN
by/IN
DTC/NN
companies/NNS
by/IN
their/PRP$
own/JJ
choice/NN
./.
====================
If/IN
conventional/JJ
genetic/JJ
testing/NN
is/VBZ
a/DT
clinician-centric/JJ
framework/NN
,/,
then/RB
DTC/NN
genetic/JJ
testing/NN
is/VBZ
a/DT
consumer-centric/JJ
one/CD
./.
====================
Normally/RB
,/,
saliva/NN
or/CC
mouth/NN
cells/NNS
obtained/VBN
by/IN
scratching/VBG
the/DT
inside/NN
of/IN
one/CD
’/NN
s/NNS
mouth/NN
with/IN
a/DT
cotton/NN
swab/NN
are/VBP
sent/JJ
to/TO
the/DT
DTC/NN
company/JJ
./.
====================
The/DT
company/JJ
isolates/NNS
DNA/NN
from/IN
the/DT
sample/NN
and/CC
conducts/VBZ
a/DT
genetic/JJ
test/NN
./.
====================
The/DT
test/NN
results/VBZ
are/VBP
analyzed/VBN
through/IN
proprietary/JJ
in-house/IN
programs/NNS
and/CC
a/DT
genetic/JJ
profile/NN
report/VBP
of/IN
various/JJ
phenotypes/NNS
is/VBZ
sent/JJ
to/TO
the/DT
consumer/NN
./.
====================
The/DT
test/NN
items/VBZ
or/CC
test/NN
report/VBP
may/MD
vary/VB
depending/VBG
on/IN
the/DT
needs/NNS
of/IN
the/DT
consumer/NN
,/,
as/IN
well/RB
as/IN
operational/JJ
characteristics/NNS
of/IN
the/DT
company/JJ
./.
====================
Conventional/JJ
clinician-centric/JJ
tests/NNS
are/VBP
aimed/VBN
at/IN
diagnosing/VBG
and/CC
treating/VBG
patients/NNS
’/CD
diseases/NNS
,/,
mainly/RB
limited/JJ
to/TO
genetic/JJ
diseases/NNS
or/CC
cancers/NNS
./.
====================
Consumer-centric/JJ
DTC/NN
tests/NNS
do/VBP
also/RB
carry/VBP
out/RP
genetic/JJ
tests/NNS
for/IN
diseases/NNS
,/,
but/CC
have/VBP
an/DT
additional/JJ
emphasis/NN
on/IN
biometric/life-related/JJ
concerns/VBZ
,/,
such/JJ
as/IN
obesity/NN
,/,
nutrition/NN
,/,
skin/NN
,/,
hair/NN
loss/NN
,/,
ancestry/NN
,/,
and/CC
life/NN
cycle/NN
./.
====================
Therefore/RB
,/,
the/DT
aim/NN
of/IN
DTC/NN
genetic/JJ
testing/NN
is/VBZ
to/TO
determine/VB
consumers/NNS
’/CD
propensity/NN
for/IN
such/JJ
phenotypes/NNS
or/CC
genetic/JJ
predisposition/NN
to/TO
the/DT
tested/VBN
diseases/NNS
for/IN
preventive/JJ
purposes/NNS
,/,
rather/RB
than/IN
for/IN
the/DT
diagnosis/NN
and/CC
treatment/NN
of/IN
diseases/NNS
./.
====================
The/DT
cost/JJ
of/IN
DTC/NN
genetic/JJ
testing/NN
varies/VBZ
from/IN
company/JJ
to/TO
company/JJ
,/,
but/CC
is/VBZ
roughly/RB
in/IN
the/DT
range/NN
of/IN
100–1,000/CD
US/NN
dollars/VBZ
,/,
and/CC
DTC/NN
genetic/JJ
testing/NN
is/VBZ
generally/RB
not/RB
covered/VBN
by/IN
insurance/NN
./.
====================
The/DT
advantages/NNS
of/IN
DTC/NN
genetic/JJ
testing/NN
can/MD
be/VB
described/VBN
as/IN
follows/VBZ
[/(
1,2/NN
]/)
./.
====================
First/RB
,/,
DTC/NN
genetic/JJ
testing/NN
may/MD
provide/VB
an/DT
opportunity/NN
for/IN
consumers/NNS
to/TO
recognize/VB
the/DT
importance/NN
of/IN
genetics/NNS
in/IN
diverse/JJ
phenotypes/NNS
,/,
including/VBG
diseases/NNS
./.
====================
If/IN
the/DT
test/NN
results/VBZ
indicate/VBP
that/IN
a/DT
consumer/NN
has/VBZ
a/DT
genetic/JJ
predisposition/NN
to/TO
a/DT
certain/JJ
disease/NN
or/CC
phenotype/NN
of/IN
interest/NN
,/,
then/RB
he/RB
or/CC
she/PRP
may/MD
take/VB
proactive/JJ
steps/NNS
to/TO
improve/VB
his/DT
or/CC
her/RB
own/JJ
health/NN
./.
====================
It/PRP
is/VBZ
easy/RB
to/TO
access/VB
genetic/JJ
information/NN
through/IN
DTC/NN
testing/NN
because/IN
it/PRP
does/VBZ
not/RB
require/VB
approval/JJ
from/IN
clinicians/NNS
or/CC
insurance/NN
companies/NNS
./.
====================
Moreover/RB
,/,
DTC/NN
genetic/JJ
testing/NN
is/VBZ
generally/RB
less/RBR
expensive/JJ
and/CC
faster/JJR
than/IN
genetic/JJ
testing/NN
performed/VBN
at/IN
hospitals/NNS
./.
====================
The/DT
sample/JJ
is/VBZ
normally/RB
collected/VBN
non-invasively/RB
,/,
such/JJ
as/IN
through/IN
gathering/VBG
saliva/NN
or/CC
scratching/VBG
the/DT
inside/NN
of/IN
one/CD
’/NN
s/NNS
mouth/NN
with/IN
a/DT
cotton/NN
swab/NN
,/,
instead/RB
of/IN
drawing/VBG
blood/NN
,/,
as/IN
is/VBZ
performed/VBN
at/IN
the/DT
hospital/JJ
./.
====================
Lastly/RB
,/,
the/DT
data/NNS
from/IN
consumers/NNS
’/CD
genetic/JJ
tests/NNS
can/MD
be/VB
collected/VBN
into/IN
valuable/JJ
databases/NNS
to/TO
help/VB
with/IN
research/NN
in/IN
related/JJ
fields/NNS
,/,
as/IN
shown/VBN
by/IN
the/DT
papers/NNS
published/VBN
by/IN
23andMe/JJ
,/,
one/CD
of/IN
the/DT
leading/VBG
DTC/NN
genetic/JJ
testing/NN
companies/NNS
in/IN
the/DT
United/JJ
States/NNS
[/(
3,4/CD
]/)
./.
====================
Nonetheless/JJ
,/,
DTC/NN
genetic/JJ
testing/NN
has/VBZ
important/JJ
drawbacks/VBZ
[/(
1,2/NN
]/)
./.
====================
DTC/NN
genetic/JJ
testing/NN
often/RB
does/VBZ
not/RB
provide/VB
conclusive/JJ
results/NNS
on/IN
whether/IN
the/DT
consumer/NN
will/MD
develop/VB
a/DT
disease/NN
or/CC
not/RB
./.
====================
Most/JJS
genetic/JJ
tests/NNS
performed/VBN
by/IN
DTC/NN
companies/NNS
are/VBP
limited/JJ
to/TO
few/JJ
major/JJ
genetic/JJ
variants/NNS
related/JJ
to/TO
the/DT
phenotypes/NNS
of/IN
interest/NN
,/,
which/WDT
leads/VBZ
to/TO
poor/JJ
discriminatory/JJ
power/JJR
./.
====================
Diseases/NNS
are/VBP
generally/RB
affected/VBN
by/IN
many/JJ
genetic/JJ
variants—in/NN
other/JJ
words/NNS
,/,
they/PRP
are/VBP
polygenic/JJ
./.
====================
In/IN
addition/NN
to/TO
genetic/JJ
factors/NNS
,/,
disease/NN
incidence/NN
is/VBZ
influenced/VBN
by/IN
environmental/JJ
and/CC
lifestyle/JJ
factors/NNS
including/VBG
age/NN
,/,
sex/NN
,/,
race/JJ
,/,
nutrition/NN
,/,
exercise/NN
,/,
and/CC
stress/NN
./.
====================
Thus/RB
,/,
DTC/NN
genetic/JJ
testing/NN
itself/PRP
does/VBZ
not/RB
guarantee/VB
that/DT
a/DT
consumer/NN
with/IN
a/DT
high/JJ
genetic/JJ
risk/NN
score/RB
will/MD
suffer/VB
from/IN
a/DT
certain/JJ
disease/NN
./.
====================
Instead/RB
,/,
it/PRP
only/RB
indicates/VBZ
that/IN
one/CD
has/VBZ
a/DT
genetic/JJ
propensity/NN
for/IN
that/DT
disease/NN
./.
====================
If/IN
one/CD
is/VBZ
affected/VBN
by/IN
favorable/JJ
environmental/JJ
factors/NNS
and/CC
has/VBZ
a/DT
lifestyle/JJ
that/DT
is/VBZ
beneficial/JJ
for/IN
that/DT
disease/NN
,/,
one/CD
may/MD
not/RB
develop/VB
the/DT
disease/NN
despite/IN
a/DT
high/JJ
genetic/JJ
risk/NN
./.
====================
On/IN
the/DT
contrary/JJ
,/,
a/DT
consumer/NN
with/IN
a/DT
low/JJ
genetic/JJ
risk/NN
may/MD
get/VB
sick/JJ
if/IN
he/DT
or/CC
she/PRP
lives/NNS
in/IN
a/DT
disease-prone/NN
environment/NN
or/CC
has/VBZ
lifestyle/JJ
factors/NNS
that/WDT
increase/VBP
susceptibility/NN
to/TO
the/DT
disease/NN
./.
====================
For/IN
example/NN
,/,
23andMe/JJ
conducts/VBZ
an/DT
APOE/NN
genetic/JJ
test/NN
in/IN
relation/NN
to/TO
Alzheimer/NN
disease/NN
./.
====================
The/DT
average/JJ
likelihood/NN
of/IN
developing/VBG
Alzheimer/NN
disease/NN
in/IN
carriers/NNS
of/IN
the/DT
relevant/JJ
allele/NN
is/VBZ
more/RBR
than/IN
twice/RB
as/IN
high/JJ
than/IN
in/IN
people/JJ
who/WP
do/VBP
not/RB
carry/VB
it/PRP
./.
====================
However/RB
,/,
not/RB
everyone/RB
with/IN
the/DT
APOE/NN
e4/NN
gene/NN
will/MD
develop/VB
Alzheimer/NN
disease/NN
,/,
and/CC
having/VBG
the/DT
APOE/NN
e2/NN
gene/NN
,/,
which/WDT
confers/VBZ
resistance/NN
to/TO
Alzheimer/NN
disease/NN
,/,
is/VBZ
likewise/JJ
not/RB
a/DT
guarantee/JJ
that/DT
one/CD
will/MD
never/RB
get/NN
Alzheimer/NN
disease/NN
./.
====================
Consumers/NNS
sometimes/RB
experience/VBP
stress/NN
when/WRB
they/PRP
receive/VBP
unexpected/JJ
test/NN
results/VBZ
,/,
especially/RB
if/IN
the/DT
results/NNS
are/VBP
related/JJ
to/TO
serious/JJ
diseases/NNS
,/,
such/JJ
as/IN
cancer/NN
[/(
5/CD
]/)
./.
====================
It/PRP
is/VBZ
recommended/VBN
that/DT
the/DT
results/NNS
of/IN
cancer/NN
genetic/JJ
testing/NN
be/VB
examined/VBN
after/IN
consultation/NN
with/IN
clinicians/NNS
,/,
since/IN
the/DT
genetic/JJ
test/NN
results/VBZ
related/JJ
to/TO
cancer/NN
may/MD
have/VB
significant/JJ
impacts/NNS
on/IN
consumers/NNS
./.
====================
There/EX
are/VBP
also/RB
many/JJ
different/JJ
genetic/JJ
variants/NNS
that/WDT
are/VBP
related/JJ
to/TO
a/DT
specific/JJ
cancer/NN
but/CC
not/RB
available/JJ
for/IN
DTC/NN
genetic/JJ
testing/NN
./.
====================
For/IN
example/NN
,/,
only/RB
three/CD
genetic/JJ
variants/NNS
are/VBP
examined/VBN
for/IN
genetic/JJ
testing/NN
of/IN
BRCA1/NN
and/CC
BRCA2/NN
conducted/VBN
by/IN
23andMe/JJ
with/IN
U.S./NNP
Food/NN
and/CC
Drug/NN
Administration/NN
approval/JJ
./.
====================
However/RB
,/,
as/IN
many/JJ
as/IN
1,000/CD
mutations/NNS
of/IN
BRCA1/NN
and/CC
BRCA2/NN
are/VBP
known/VBN
to/TO
affect/VB
the/DT
risk/NN
of/IN
breast/NN
and/CC
ovarian/JJ
cancer/NN
./.
====================
Furthermore/RB
,/,
family/NN
history/NN
is/VBZ
known/VBN
to/TO
explain/VB
only/RB
about/RB
5/CD
%/NN
–10/CD
%/NN
of/IN
cancer/NN
cases/NNS
./.
====================
A/DT
wide/JJ
variety/NN
of/IN
factors/NNS
,/,
including/VBG
age/NN
,/,
sex/NN
,/,
nutrition/NN
,/,
exercise/VBP
,/,
race/RB
,/,
disease/NN
history/JJ
,/,
hormonal/JJ
factors/NNS
,/,
and/CC
reproductive/JJ
factors/NNS
,/,
can/MD
affect/VB
the/DT
development/NN
of/IN
cancer/NN
./.
====================
Consumers/NNS
may/MD
make/VB
decisions/NNS
on/IN
their/PRP$
own/JJ
with/IN
inaccurate/JJ
or/CC
non-deterministic/JJ
DTC/NN
results/NNS
,/,
and/CC
take/VBP
actions/NNS
that/DT
can/MD
damage/VB
their/PRP$
health/NN
without/IN
appropriate/JJ
consultation/NN
with/IN
clinicians/NNS
./.
====================
Lastly/RB
,/,
there/EX
is/VBZ
often/RB
a/DT
lack/NN
of/IN
scientific/JJ
evidence/NN
for/IN
the/DT
genetic/JJ
tests/NNS
carried/VBD
out/RP
by/IN
DTC/NN
companies/NNS
,/,
and/CC
consumers/VBZ
’/CD
genetic/JJ
information/NN
may/MD
be/VB
used/VBN
for/IN
other/JJ
purposes/NNS
without/IN
their/PRP$
approval/JJ
or/CC
might/MD
even/RB
be/VB
stolen/VBN
due/JJ
to/TO
inappropriate/JJ
security/NN
measures/NNS
./.
====================
The/DT
discovery/NN
of/IN
genetic/JJ
variations/NNS
in/IN
diseases/NNS
or/CC
phenotypes/NNS
of/IN
interest/NN
(/(
e.g./FW
,/,
weight/NN
,/,
hair/NN
loss/NN
,/,
intelligence/NN
,/,
etc/JJ
./.
)/)
====================
is/VBZ
quickly/RB
paying/VBG
off/JJ
./.
====================
Clinical/JJ
applications/NNS
have/VBP
focused/VBN
on/IN
predictive/JJ
models/NNS
of/IN
disease/NN
./.
====================
Previously/RB
,/,
disease/NN
predictions/NNS
were/VBD
made/VBN
using/VBG
a/DT
few/JJ
genetic/JJ
variants/NNS
that/IN
showed/VBD
significance/NN
in/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
,/,
on/IN
which/WDT
basis/NN
a/DT
polygenic/JJ
score/RB
(/(
PGS/NN
)/)
was/VBD
calculated/VBN
./.
====================
Most/JJS
predictions/NNS
resulted/VBD
in/IN
poor/JJ
discrimination/NN
and/CC
imprecision/NN
./.
====================
Predictive/JJ
models/NNS
are/VBP
gradually/RB
starting/VBG
to/TO
use/VB
more/RBR
genetic/JJ
variants/NNS
,/,
as/IN
GWASs/NNS
are/VBP
discovering/VBG
more/RBR
genetic/JJ
variations/NNS
as/IN
a/DT
consequence/NN
of/IN
using/VBG
an/DT
increased/VBN
number/NN
of/IN
samples/NNS
,/,
and/CC
recently/RB
developed/VBN
predictive/JJ
models/NNS
take/VBP
into/IN
account/VBP
genome-wide/NN
variations/NNS
,/,
calculating/JJ
a/DT
genome-wide/JJ
polygenic/JJ
score/RB
(/(
GPS/NN
)/)
./.
====================
In/IN
a/DT
study/NN
using/VBG
a/DT
GPS/NN
for/IN
body/NN
mass/NN
index/NN
,/,
the/DT
people/JJ
with/IN
the/DT
highest/JJS
score/RB
category/NN
had/VBD
an/DT
obesity/NN
prevalence/NN
rate/NN
four/CD
times/NNS
higher/JJR
than/IN
that/DT
of/IN
the/DT
other/JJ
categories/NNS
[/(
6/CD
]/)
./.
====================
Thus/RB
,/,
the/DT
GPS/NN
method/NN
has/VBZ
yielded/VBD
better/RBR
predictions/NNS
than/IN
ever/RB
before/IN
./.
====================
The/DT
most/JJS
worrisome/NN
factor/NN
of/IN
all/DT
relates/VBZ
to/TO
the/DT
reporting/VBG
of/IN
genetic/JJ
test/NN
results/VBZ
./.
====================
The/DT
results/NNS
of/IN
DTC/NN
genotyping/VBG
should/MD
be/VB
clearly/RB
communicated/VBN
to/TO
the/DT
consumer/NN
;/:
in/IN
particular/JJ
,/,
clear/JJ
guidance/NN
should/MD
be/VB
given/VBN
regarding/VBG
what/WP
these/DT
tests/NNS
indicate/VBP
about/IN
their/PRP$
illness/NN
or/CC
health/NN
and/CC
what/WP
they/PRP
can/MD
not/RB
show/VB
,/,
with/IN
special/JJ
emphasis/NN
on/IN
the/DT
fact/NN
that/IN
these/DT
tests/NNS
can/MD
not/RB
be/VB
a/DT
diagnosis/NN
of/IN
disease/NN
./.
====================
Consumers/NNS
may/MD
make/VB
decisions/NNS
on/IN
their/PRP$
own/JJ
based/VBN
on/IN
inaccurate/JJ
or/CC
non-deterministic/JJ
DTC/NN
results/NNS
,/,
and/CC
may/MD
even/RB
take/VBP
actions/NNS
that/DT
can/MD
damage/VB
their/PRP$
health/NN
without/IN
appropriate/JJ
consultation/NN
with/IN
clinicians/NNS
./.
====================
DTC/NN
companies/NNS
should/MD
therefore/RB
inform/VBP
consumers/NNS
of/IN
the/DT
limitations/NNS
of/IN
the/DT
test/NN
results/VBZ
and/CC
encourage/VBP
consumers/NNS
to/TO
consult/VB
with/IN
clinicians/NNS
before/IN
taking/VBG
action/NN
./.
====================
Many/JJ
of/IN
the/DT
concerns/NNS
mentioned/JJ
above/JJ
as/IN
shortcomings/VBZ
of/IN
DTC/NN
genetic/JJ
testing/NN
remain/VBP
pending/JJ
./.
====================
At/IN
this/DT
point/NN
,/,
the/DT
guidelines/NNS
provided/VBD
by/IN
the/DT
American/NN
College/NN
of/IN
Medical/JJ
Genetics/NNS
and/CC
Genomics/NNS
for/IN
DTC/NN
genotyping/VBG
are/VBP
as/IN
follows/VBZ
[/(
7/CD
]/)
./.
====================
First/RB
,/,
genetic/JJ
testing/NN
and/CC
the/DT
interpretation/NN
of/IN
results/NNS
are/VBP
complex/NN
processes/NNS
./.
====================
Thus/RB
,/,
genetic/JJ
testing/NN
should/MD
be/VB
performed/VBN
in/IN
a/DT
laboratory/JJ
that/IN
has/VBZ
been/VBN
inspected/VBN
by/IN
an/DT
appropriate/JJ
agency/NN
,/,
such/JJ
as/IN
the/DT
CLIA/NN
program/NN
in/IN
the/DT
United/JJ
States/NNS
./.
====================
In/IN
addition/NN
,/,
genetic/JJ
experts/NNS
,/,
such/JJ
as/IN
clinical/JJ
geneticists/NNS
or/CC
genetic/JJ
counselors/NNS
,/,
should/MD
handle/NN
requests/VBZ
from/IN
consumers/NNS
and/CC
the/DT
provision/NN
of/IN
test/NN
results/VBZ
./.
====================
They/PRP
will/MD
protect/VB
consumers/NNS
from/IN
improper/JJ
informed/VBN
consent/NN
procedures/NNS
,/,
a/DT
lack/NN
of/IN
pre-test/JJS
descriptions/NNS
,/,
incorrect/VBP
genetic/JJ
test/NN
items/VBZ
,/,
and/CC
inappropriate/JJ
precautions/NNS
or/CC
medical/JJ
practices/NNS
resulting/VBG
from/IN
the/DT
misinterpretation/NN
of/IN
test/NN
results/VBZ
./.
====================
Second/RB
,/,
consumers/VBZ
should/MD
be/VB
informed/VBN
by/IN
the/DT
DTC/NN
company/JJ
of/IN
what/WP
the/DT
test/NN
results/VBZ
can/MD
and/CC
can/MD
not/RB
do/VBP
before/IN
DTC/NN
genotyping/VBG
./.
====================
Third/RB
,/,
the/DT
DTC/NN
company/JJ
should/MD
explain/VB
that/DT
unexpected/JJ
,/,
or/CC
unrequested/JJ
,/,
results/VBZ
may/MD
come/VB
from/IN
genotyping/VBG
./.
====================
Consumers/NNS
should/MD
also/RB
be/VB
informed/VBN
that/DT
these/DT
unforeseen/JJ
consequences/NNS
can/MD
affect/VB
not/RB
only/RB
themselves/DT
,/,
but/CC
also/RB
their/PRP$
family/NN
members/NNS
./.
====================
Fourth/DT
,/,
the/DT
DTC/NN
company/JJ
should/MD
inform/VB
the/DT
consumer/NN
about/RB
the/DT
scientific/JJ
basis/NN
upon/IN
which/WDT
the/DT
genetic/JJ
test/NN
was/VBD
conducted/VBN
./.
====================
If/IN
this/DT
is/VBZ
too/RB
technical/JJ
for/IN
the/DT
general/JJ
public/JJ
to/TO
understand/VB
,/,
it/PRP
should/MD
be/VB
explained/VBN
in/IN
a/DT
way/NN
that/DT
facilitates/VBZ
easy/RB
understanding/NN
./.
====================
Fifth/DT
,/,
consumers/VBZ
should/MD
receive/JJ
the/DT
following/VBG
information/NN
as/IN
part/NN
of/IN
an/DT
explanation/NN
about/RB
personal/JJ
information/NN
protection/NN
:/:
who/WP
will/MD
see/VB
the/DT
results/NNS
of/IN
a/DT
consumer/JJ
’/NNP
s/NNS
genetic/JJ
test/NN
,/,
what/WP
measures/VBZ
will/MD
be/VB
taken/VBN
to/TO
protect/VB
the/DT
genetic/JJ
information/NN
,/,
how/RB
the/DT
sample/JJ
will/MD
be/VB
processed/VBN
after/IN
it/PRP
is/VBZ
used/VBN
,/,
how/RB
the/DT
genetic/JJ
test/NN
results/VBZ
will/MD
subsequently/RB
affect/VBP
life/JJ
insurance/RB
or/CC
disability/JJ
insurance/RB
,/,
who/WP
owns/VBZ
the/DT
genetic/JJ
information/NN
produced/VBN
,/,
and/CC
whether/IN
the/DT
genetic/JJ
information/NN
can/MD
be/VB
provided/VBN
to/TO
third/JJ
parties/NNS
./.
====================
DTC/NN
genetic/JJ
testing/NN
provides/VBZ
consumers/NNS
with/IN
the/DT
opportunity/NN
to/TO
learn/VB
about/RB
their/PRP$
genetic/JJ
profiles/NNS
related/JJ
to/TO
phenotypes/NNS
of/IN
interest/NN
in/IN
a/DT
convenient/JJ
and/CC
less/RBR
expensive/JJ
manner/NN
./.
====================
Furthermore/RB
,/,
the/DT
list/NN
of/IN
test/NN
items/VBZ
will/MD
increase/VB
and/CC
the/DT
predictive/JJ
accuracy/NN
will/MD
be/VB
improved/VBN
as/IN
related/JJ
research/NN
continues/NNS
to/TO
progress/VB
rapidly/RB
./.
====================
However/RB
,/,
many/JJ
of/IN
the/DT
concerns/NNS
previously/RB
mentioned/JJ
as/IN
shortcomings/VBZ
of/IN
DTC/NN
genetic/JJ
testing/NN
remain/VBP
pending/JJ
./.
====================
While/IN
DTC/NN
companies/NNS
should/MD
try/NN
to/TO
compensate/VB
for/IN
these/DT
shortcomings/NNS
themselves/DT
to/TO
the/DT
extent/NN
possible/JJ
,/,
regulation/NN
over/IN
DTC/NN
companies/NNS
should/MD
be/VB
established/VBN
by/IN
the/DT
appropriate/JJ
agency/NN
to/TO
safeguard/JJ
consumers/NNS
from/IN
the/DT
abuse/JJ
of/IN
DTC/NN
genetic/JJ
testing/NN
./.
====================
